Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain on-track Company to host conference call today, Tuesday, February 26, at 4:30 p.m.
Equillium to Present at Leerink Partners Global Healthcare Conference
LA JOLLA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, announced today that Bruce Steel, Equillium’s president and chief business officer, will present at the Leerink Partners 8 th
Equillium to Host Business Update Call on February 26
LA JOLLA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with shareholders and the investment community to provide a business update on Tuesday, February 26,
Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designations for EQ001 for both the